.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06B_Immunoglobulins.J06BD06_Regdanvimab.Regdanvimab .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06B_Immunoglobulins.J06BD06_Regdanvimab.Regdanvimab| name: | Regdanvimab | |
| ATC code: | J06BD06 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 4000 | mg |
| volume of distribution: | 4.5 | L |
| clearance: | 0.296 | L/day |
| other parameters in model implementation | ||
Regdanvimab is a recombinant human monoclonal antibody targeting the receptor binding domain of the SARS-CoV-2 spike protein. It is used for the treatment of mild-to-moderate COVID-19 in certain patients and has received emergency or conditional authorizations in several countries.
Pharmacokinetic parameters reported in adults with COVID-19 following a single intravenous infusion.